21.04.2022 | Published by Charles River Vital Science
Charles River Vital Science podcast talks to CEO Mark Kotter
bit.bio CEO Dr Mark Kotter, discusses how he's overseen the development of a unique approach to "reprogram" stem cells withopti-oxTMtechnology and how bit.bio can change them into consistent and scalable disease-relevant cells, which can then be screened for potential therapeutics to help treat such diseases as Huntington's, Alzheimer's, and ALS.
Hear about this revolutionary technology and how it works, what benefits it can provide researchers, and how it could very well shape the future of drug development.
About usCoding cells to advance the wellbeing of humanity